REBEL Core Cast 85.0 – Superficial Venous Thrombosis
Take Home Points SVT >5cm or <3 cm from the SFJ should be treated with anti-coagulation. The rate of concurrent DVT and PE in patients with SVT is 25% and 5%, respectively.
Take Home Points SVT >5cm or <3 cm from the SFJ should be treated with anti-coagulation. The rate of concurrent DVT and PE in patients with SVT is 25% and 5%, respectively.
Background: The optimal approach to risk stratifying patients for pulmonary embolism (PE) remains elusive. Multiple decision instruments are available with varying degrees of complexity and acceptance among emergency medicine clinicians (Wells, Geneva, PERC, YEARS, age-adjusted D-dimer). The 2018 ACEP clinical …
Early reports have shown that COVID-19 is most likely causing a hypercoagulable state, however the prevalence of acute VTE and exactly how to treat it is an evolving area. Limited data suggest pulmonary microvascular thrombosis may play a role in …
Background: Venous thromboembolism (VTE) occurs frequently in patient with cancer. Treatment in this group entails a number of challenges including a higher rate of thrombosis recurrence and a higher risk of bleeding. Standard therapy in 2018 for both symptomatic and …
Background: Venous thromboembolism (VTE) occurs frequently in patient with cancer. Treatment in this group entails a number of challenges including a higher rate of thrombosis recurrence and a higher risk of bleeding. Standard therapy at this time for both symptomatic …
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.